Logos Global Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Logos Global Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,125,000	Closed	-$84.4M	–	73
2026 Q1	$84.4M	Buy	2,125,000 +1,925,000	+963%	+$49.2M	4.21%	5
2025 Q4	$5M	Sell	200,000 -325,000	-62%	-$8.23M	0.3%	54
2025 Q3	$12.7M	Buy	+525,000	New	+$9.33M	1.14%	33
2022 Q4	–	Sell	-399,801	Closed	-$1.61M	–	44
2022 Q3	$1.61M	Hold	399,801	–	–	0.2%	32
2022 Q2	$1.95M	Sell	399,801 -54,744	-12%	-$350K	0.36%	21
2022 Q1	$4.08M	Hold	454,545	–	–	0.53%	27
2021 Q4	$5.12M	Sell	454,545 -615,000	-58%	-$8.27M	0.53%	41
2021 Q3	$17.9M	Buy	1,069,545 +130,000	+14%	+$2.69M	1.29%	24
2021 Q2	$20.9M	Buy	+939,545	New	+$22.1M	1.75%	22

Logos Global Management's CNTA Position: Q2 2026 in Review

Logos Global Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 2,125,000 shares — an estimated $84.4M sold.

Logos Global Management first reported a position in CNTA in Q2 2021 and held it in 9 quarters. The position peaked at $84.4M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Logos Global Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Logos Global Management sold 2,125,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $84.4M.
Logos Global Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Logos Global Management's Centessa Pharmaceuticals position peaked at $84.4M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.